aTYR PHARMA INC Income Statement
ATYR|7 years of annual SEC 10-K data (FY2019-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 7 fiscal years. All figures from audited SEC 10-K filings.
aTYR PHARMA INC reported $190,000 in revenue and $74M in net loss for FY2025. Revenue has declined at a 12.5% compound annual rate over the past 6 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -6.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $190.0K | $235.0K | $0 | $10.5M | $422.0K | $422.0K | $422.0K |
| SG&A Expense | $17.6M | $13.8M | $10.8M | $9.1M | $9.4M | $12.4M | $17.1M |
| R&D Expense | $60.2M | $54.4M | $23.3M | $17.3M | $14.0M | $20.4M | $30.1M |
| Operating Income | -$77.6M | -$67.9M | -$34.0M | -$15.9M | -$23.0M | -$32.8M | -$47.1M |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | - |
| Net Income | -$74.1M | -$64.0M | -$33.8M | -$16.2M | -$23.6M | -$34.5M | -$48.2M |
| EPS (Basic) | -$0.94 | -$1.60 | -$1.77 | -$1.77 | - | - | - |
| EPS (Diluted) | -$0.94 | -$1.60 | -$1.77 | -$1.77 | -$7.03 | -$16.11 | -$26.13 |
| Shares Outstanding | 84.0M | 63.3M | 29.5M | 27.8M | 11.0M | 3.9M | 2.2M |
| Operating Margin | -40856.3% | -28899.6% | - | -152.2% | -5445.0% | -7777.2% | -11171.8% |
| Profit Margin | -39009.5% | -27243.8% | - | -155.2% | -5593.1% | -8178.9% | -11423.5% |